Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ahmet Küçükarda"'
Autor:
Birol Ocak, Ahmet Bilgehan Sahin, Ismail Ertürk, Mustafa Korkmaz, Dilek Erdem, Umut Cakıroglu, Mustafa Karaca, Ahmet Dirican, Omer Fatih Olmez, Sabin Goktas Aydın, Ali Gökyer, Ahmet Kücükarda, Ahmet Gülmez, Perran Fulden Yumuk, Nazim Can Demircan, Abdilkerim Oyman, Teoman Sakalar, Fatih Karatas, Hacer Demir, Ayse Irem Yasin, Adem Deligonul, Bahar Dakiki, Mehmet Refik Goktug, Okan Avcı, Seher Yildiz Tacar, Nazım Serdar Turhal, Gülhan Ipek Deniz, Turgut Kacan, Erdem Cubukcu, Türkkan Evrensel
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5195-5205 (2024)
Background: This study aimed to investigate the effect of cytoreductive nephrectomy (CN) on the survival outcomes of nivolumab used as a subsequent therapy after the failure of at least one anti-vascular endothelial growth factor (VEGF) agent in pati
Externí odkaz:
https://doaj.org/article/e3b91b5047204acf948136cd657f8dec
Autor:
Birsen Sahip, Mehmet Celik, Semra Ayturk, Ahmet Kucukarda, Onur Mert, Nejla Dincer, Sibel Guldiken, Armagan Tugrul
Publikováno v:
Indian Journal of Dermatology, Vol 61, Iss 1, Pp 120-120 (2016)
Glucocorticoids are used for the treatment of many diseases, such as inflammatory, allergic, autoimmune, and neoplastic diseases. They can be used in the form of topical, oral, inhalable, rectal, and intra-articular agents. Many topical steroid-relat
Externí odkaz:
https://doaj.org/article/fb9b60352f8941faa332a513e36494d7
Autor:
Kadriye Bir Yücel, Emre Yekedüz, Serdar Karakaya, Deniz Tural, İsmail Ertürk, Cihan Erol, Özlem Ercelep, Nihan Şentürk Öztaş, Çağatay Arslan, Gökhan Uçar, Ahmet Küçükarda, Özlem Nuray Sever, Saadettin Kılıçkap, Orçun Can, Satı Coşkun Yazgan, Berna Öksüzoğlu, Nuri Karadurmuş, Mehmet Ali Şendur, Yüksel Ürün
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract This study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated with tyrosine kin
Externí odkaz:
https://doaj.org/article/ff731989e9c14a97850334af8794a507
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 7, Iss 2, Pp 128-132 (2019)
Aim:Pure seminoma which is diagnosed in early stages is the most important tumor seen in young adults. Toxicity problems and patient preferences should be taken into consideration when making treatment decision. We aimed to present the data and survi
Externí odkaz:
https://doaj.org/article/f47cdbdc4c8e48b7b841d782ae0402e3
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 1, Iss , Pp 100010- (2020)
Introduction: Colovesical fistulas are one of the most frequent complications in fistulizing Crohn's disease. Fistulizing Crohn's disease and tumor coexistence may lead to tumor spread through the fistula. Case report: In this study, a 62-year-old ma
Externí odkaz:
https://doaj.org/article/40170425749d4daa9f15e4924fbde184
Autor:
Cihan Erol, Emre Yekedüz, Deniz Tural, Serdar Karakaya, Nihan Şentürk Öztaş, Gökhan Uçar, Saadettin Kılıçkap, İsmail Ertürk, Özlem Nuray Sever, Çağatay Arslan, Ahmet Küçükarda, Orçun Can, Özlem Balvan, Satı Coşkun Yazgan, Mustafa Özgüroğlu, Berna Öksüzoğlu, Mehmet Ali Nahit Şendur, Yüksel Ürün
Publikováno v:
Urologia Internationalis. :1-7
Introduction: We aimed to evaluate clinical features, prognostic factors, and treatment preferences in patients with non-clear cell renal cell carcinoma (nccRCC). Methods: Patients with metastatic nccRCC were selected from the Turkish Oncology Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bf0bfca5db9383fcb30bc0a60930218
https://doi.org/10.1159/000528994
https://doi.org/10.1159/000528994
Autor:
İBRAHİM ETHEM CAKCAK, YUSUF EMRE AYTİN, SEZİN SAYIN, AHMET KÜÇÜKARDA, ALİ GÖKYER, İVO GÖKMEN, ERKAN ÖZCAN, SELÇUK KORKMAZ, EBRU TAŞTEKİN, İRFAN ÇİÇİN
Publikováno v:
Turkish Journal of Medical Sciences. 53:51-57
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff1d1e0d88dbb6602acdfecc329495b6
https://doi.org/10.55730/1300-0144.5557
https://doi.org/10.55730/1300-0144.5557
Autor:
Birol Ocak, Ahmet Bilgehan Sahin, Ismail Ertürk, Mustafa Korkmaz, Dilek Erdem, Umut Cakıroglu, Mustafa Karaca, Ahmet Dirican, Omer Fatih Olmez, Sabin Göktaş Aydın, Ali Gökyer, Ahmet Küçükarda, Ahmet Gülmez, Perran Fulden Yumuk, Nazim Can Demircan, Abdilkerim Oyman, Teoman Sakalar, Fatih Karataş, Hacer Demir, Ayse Irem Yasin, Adem Deligönül, Bahar Dakiki, Mehmet Refik Goktug, Okan Avcı, Seher Yildiz Tacar, Nazım Serdar Turhal, Gulhan Ipek Deniz, Turgut Kacan, Erdem Cubukcu, Türkkan Evrensel
Renal cell carcinoma is the fourteenth most common cancer in the world with a male to female ratio of 2:1, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Nivolumab is preferred as subsequent therapy in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e5a15870b5d76209b99a5b795b3e4bc
https://doi.org/10.21203/rs.3.rs-1693977/v1
https://doi.org/10.21203/rs.3.rs-1693977/v1
Autor:
Emre Yekedüz, Serdar Karakaya, İsmail Ertürk, Deniz Tural, Gökhan Uçar, Nihan Şentürk Öztaş, Rukiye Arıkan, Mutlu Hızal, Ahmet Küçükarda, Özlem Nuray Sever, Çağatay Arslan, Orçun Can, Saadettin Kılıçkap, Coşkun Yazgan, Nuri Karadurmuş, Mehmet Ali Şendur, İrfan Çiçin, Umut Demirci, Mustafa Özgüroğlu, Berna Öksüzoğlu, Yüksel Ürün
Publikováno v:
Clinical genitourinary cancer.
Background: A novel prognostic model was recommended for patients with metastatic RCC (mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to externally validate a novel risk model for the IMDC-favorable risk group in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ebfad32a5df7fb32632e57b213e379d
https://pubmed.ncbi.nlm.nih.gov/35970759
https://pubmed.ncbi.nlm.nih.gov/35970759
Autor:
Emre Yekedüz, Deniz Tural, İsmail Ertürk, Serdar Karakaya, Cihan Erol, Özlem Ercelep, Çağatay Arslan, Özlem Nuray Sever, Saadettin Kılıçkap, Nihan Şentürk Öztaş, Ahmet Küçükarda, Orçun Can, Berna Öksüzoğlu, Mehmet Ali Şendur, Nuri Karadurmuş, Yüksel Ürün
Publikováno v:
Journal of cancer research and clinical oncology. 148(12)
Background Pan-immune-inflammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81f799bd4c98740f3f062efe6fa14d8
https://pubmed.ncbi.nlm.nih.gov/35616728
https://pubmed.ncbi.nlm.nih.gov/35616728